fda warning letters compounded semaglutide tirzepatide september 2025 to Restrict Ingredients Used in Mass-Marketed GLP-1s, Crack Down on Misleading Ads FDA Drug Recalls and Warnings:

And, although no data currently exists, consideration should also be given to a potential impact on the absorption of oral hormone replacement therapy

Columbo JA, Daya N, Colantonio LD, Wang Z, Foti K, Hyacinth HI, et al

The dual GIP/GLP-1 mechanism of tirzepatide produces different receptor activation patterns compared to semaglutide, which is GLP-1-only

Interpretation with a qualified provider supports informed decision-making

Differential acute postprandial effects of processed meat and isocaloric vegan meals on the gastrointestinal hormone response in subjects suffering from type 2 diabetes and healthy controls: a randomized crossover study

Yes, but doctors need to be careful